Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramon Colomer

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 17, 2010
Selection of extreme phenotypes: the role of clinical observation in translational researchJosé Luis Pérez-Gracia, Alfonso Gúrpide, María Gloria Ruiz-Ilundain, et al.
Eclinicalmedicine|June 12, 2023
Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgementRamon Colomer, Jesús Miranda, Nuria Romero-Laorden, et al.
BMC Cancer|May 11, 2007
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cellsJavier A Menendez, Alejandro Vazquez-Martin, Ramon Colomer, et al.
Rare Tumors|January 21, 2016
Dermatofibrosarcoma Protu-Berans with Lung Metastasis Requiring PneumonectomyAna Collazo Lorduy, Berta Obispo, Karen Villar, et al.
Breast Cancer Research : BCR|February 13, 2021
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1Silvana Mouron, Luis Manso, Eduardo Caleiras, et al.
The Oncologist|February 3, 2019
Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position StatementRamon Colomer, Cristina Saura, Pedro Sánchez-Rovira, et al.
Clinical Colorectal Cancer|July 3, 2019
Safety and Oncological Outcomes of Bevacizumab Therapy in Patients With Advanced Colorectal Cancer and Self-expandable Metal StentsVilma Pacheco-Barcia, Rebeca Mondéjar, Olga Martínez-Sáez, et al.
Breast Cancer Research : BCR|December 20, 2011
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell linesTeresa Puig, Helena Aguilar, Sílvia Cufí, et al.
Journal for Immunotherapy of Cancer|September 9, 2020
A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapySantiago Sánchez-Alonso, Giulia Setti-Jerez, Montserrat Arroyo, et al.
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia|April 1, 2018
[Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology]José Palacios Calvo, Joan Albanell, Federico Rojo, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 17, 2010
Selection of extreme phenotypes: the role of clinical observation in translational researchJosé Luis Pérez-Gracia, Alfonso Gúrpide, María Gloria Ruiz-Ilundain, et al.
Eclinicalmedicine|June 12, 2023
Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgementRamon Colomer, Jesús Miranda, Nuria Romero-Laorden, et al.
BMC Cancer|May 11, 2007
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cellsJavier A Menendez, Alejandro Vazquez-Martin, Ramon Colomer, et al.
Rare Tumors|January 21, 2016
Dermatofibrosarcoma Protu-Berans with Lung Metastasis Requiring PneumonectomyAna Collazo Lorduy, Berta Obispo, Karen Villar, et al.
Breast Cancer Research : BCR|February 13, 2021
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1Silvana Mouron, Luis Manso, Eduardo Caleiras, et al.
The Oncologist|February 3, 2019
Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position StatementRamon Colomer, Cristina Saura, Pedro Sánchez-Rovira, et al.
Clinical Colorectal Cancer|July 3, 2019
Safety and Oncological Outcomes of Bevacizumab Therapy in Patients With Advanced Colorectal Cancer and Self-expandable Metal StentsVilma Pacheco-Barcia, Rebeca Mondéjar, Olga Martínez-Sáez, et al.
Breast Cancer Research : BCR|December 20, 2011
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell linesTeresa Puig, Helena Aguilar, Sílvia Cufí, et al.
Journal for Immunotherapy of Cancer|September 9, 2020
A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapySantiago Sánchez-Alonso, Giulia Setti-Jerez, Montserrat Arroyo, et al.
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia|April 1, 2018
[Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology]José Palacios Calvo, Joan Albanell, Federico Rojo, et al.
Pageof 8